Letters
Sentinel node biopsy for melanoma
Call for a balanced view on sentinel node biopsy for melanoma
BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f648 (Published 06 February 2013) Cite this as: BMJ 2013;346:f648
- Jenny L C Geh, consultant plastic surgeon1,
- Ciaran Healy, consultant plastic surgeon1,
- Katie Lacy, consultant dermatologist1,
- Mary Wain, consultant dermatologist1,
- Natalie Attard, consultant dermatologist1,
- Eduardo Calonje, consultant dermatopathologist,
- Mark Harries, consultant oncologist1,
- Michael O’Doherty, consultant in nuclear medicine1,
- Danuta Orlowska, clinical psychologist for skin cancer service1
- 1Guy’s and St Thomas’ NHS Foundation Trust, St Thomas’ Hospital, London SE1 7EH, UK
- jenny.geh{at}gstt.nhs.uk
The title of Torjesen’s article could be misleading.1 Sentinel node biopsy (SNB) is a staging tool used to provide patients with the best available information,2 and is a well established prognostic test.
Our research shows that patients want information on prognosis.3 Lymph node status is the most meaningful prognostic indicator and SNB the most sensitive …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.